chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left  eye redness of 1 day(s)  duration with purulence and mattering.  She reports no vision problems such as blurred vision.  She does report some Left eye discomfort. Treatment = Ofloxacin ophthalmic solution 0.3% 2 drops to right left both eyes 4 times a day for 5 days. Eye problem was also addressed: 3/20/21 at urgent care  "Treated for conjunctivitis with ofloxacin 1 week ago.  Possibly some problem getting the drops in but things were improving until today when she awoke with recurrent symptoms of left eye redness and watering and matting. Treatment = Erythromycin ointment nightly. 03/22/21 03/24/21 03/26/21 Patient was then seen by an Ophthalmologist 04/02/21: " Patient came in today with symptoms of a red irritated teary photophobic swollen left eye.  The eye is hard for her to open.  Symptoms started March 11th.  Patient has been given antibiotic drops, erythromycin ointment, up to the OR, Bleph 10 none which helped her.  Patient also was given Zyrtec and Flonase  Diagnosis: Blepharoconjunctivitis  Treatment TobraDex q.i.d.  Lid scrubs  Recheck 1 week  Patient was then seen by an Ophthalmologist 04/09/21: "Recheck blepharoconjunctivitis of the left eye, I is much improved no more redness or discharge  External Eye Exam: normal DX:  Blepharoconjunctivitis  Treatment :  Decrease TobraDex  To bid for 1 week then stop   cont  Lid scrubs prn  Recheck 1 week PATIENT RECEIVED 2ND PFIZER VACCINE 04/09/21  Patient saw another ophthalmologist 04/12/21: "OS red, irritated off/on x 1 mo Saw UC, PCP, OD, etc  --was doing much better at lv 4/09 w MP ** --advised to taper TD gtts   COVID Vaccine later in day 4/09 + GI symptoms(nausea, dry heaves)** -- > ER  However, OS got much worse 4/10 More red, sore, Blurry Some tearing, no discharge Diagnosis and Treatment: Findings consistent with:  1) Acute iritis of left eye  2) Secondary ACUTE angle-closure glaucoma of left eye, unspecified glaucoma stage + IRIS BOMBE**   Diamox 500 mg po in office --1 gtt :  Timolol x 2 Brimonidine x 2 Prednisolone Acetate x 4 NEO, CYCL X 2   Patient was seen by PCP Dr 04/13/21: "Parents report an issue with her left eye x1 month.  Thought to be pink eye.  Was treated without resolution.  Eventually saw Ophthalmology.  Elevated pressures noted in the left eye and diagnosis of iritis given.  Diagnosed with acute angle closure glaucoma due to secondary reasons.  Of note is that patient received COVID vaccination on April 9th.  This was followed by nausea and retching which took her to the ER on 04/10.  There is thought that maybe this retching caused elevated eye pressures.  She is currently on Diamox/timolol/prednisone/brimonidine.  Parents do think that the redness and the swelling in the left eye is improving and they have a follow-up appointment with Ophthalmology today." Assessment:  Left eye iritis/secondary acute angle closure glaucoma-ophthalmology appointment today-unclear chronicity of glaucoma-increased pressures may be due to recent nausea and retching from COVID vaccination  patient has been seen 16 more times since these occurrances
Information has been received from a registered nurse referring to a male patient of unknown age. The patient's pertinent medical history, concurrent conditions or drug reactions/allergies were unknown by reporter. On an unknown date, the patient was vaccinated with M-M-R II (dose 1, lot number and route not provided). Following that administration, the patient received a "stem cell transplant" in 2014 (reported as "two years ago") due to the development of an unspecified type of cancer. The primary reporter also stated that the unknown patient was administered a second dose of M-M-R II (lot number and route not provided) on 20-JUL-2016. The outcome of event was unknown. Upon internal review,  the event stem cell transplant  due to the development of an unspecified type of cancer was considered to be medically significant. Additional information has been requested.
Intussusception: multiple hours' worth of sudden and severe waves of extreme pain (causing syncope), diarrhea, pallor.
My trigeminal neuralgia became more intense with pain to right side of face; My trigeminal neuralgia became more intense with pain to right side of face; pain was too intense; This is a spontaneous report from a contactable consumer (patient). A 77-years-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot number and Expiry date was not reported) dose 2 via an unspecified route of administration in left arm on 08Jun2021 11:30 (age at vaccination was 77-year-old) for covid-19 immunization. The patient had no known allergies. Medical history included heart diabetes, DVT (deep vein thrombosis), PAD (peripheral arterial occlusive disease), trigeminal neuralgia. Patient previously received dose 1 (Lot number and Expiry date was not reported) via an unspecified route administration in left arm on 18May 11.30 AM as single dose for covid-19 immunization. Facility where the most recent COVID-19 vaccine was administered in Pharmacy or Drug Store. Concomitant medications received within 2 weeks of vaccination was atorvastatin (ATORVASTATIN), cholecalciferol (CHOLECALCIFEROL), gabapentin (GABAPENTIN), glimepiride (GLIMEPIRIDE). The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 09Jun2021 patient experienced trigeminal neuralgia became more intense with pain to right side of face, notified Doctor of pain and made 3 trips to ER 2 by ambulance as the pain was too intense. Treatment received for the events was oxycodone, morpheein, Vicodin. Since the vaccination, patient has not been tested for COVID-19. The outcome of the event was not resolved. Information on the lot/batch number has been requested. Additional information is expected.
This case was reported by a nurse and described the occurrence of autism in a 19 month old male pt who received hep B vaccine recombinant (Engerix B) and Infanrix. On an unspecified date in July 2000, the pt received the first dose of hep B vaccine. Approximately one month later, in August 2000, the pt received the second dose of hep B vaccine. On an unspecified date, the pt received the third dose of hep B vaccine. On unspecified dates, the pt received a series of three doses of Infanrix. On 2/2/02, the pt was diagnosed with autism and "mercury in his body he cannot excrete." The events were unresolved. Comment: This case was considered medically serious (OMIC) by manufacturer. On 19 February 2003 the patient was diagnosed with autism and questionable mercury poisioning. The nurse initially reported that the patient had "mercury in his body he connot excrete". On follow-up the nurse indicated that it was uncertain whether mercury was being retained, and diagnostic results were pending. The patient's developmental delays were unresolved at the time of reporting. In the nurse's opinion the events which were considered to be disabling were unrelated to Engerix-B or Infanrix. Information fron Annual Follow-up report states developmental delays persist.
blocked arteries in his right leg  2 out of 3 blocked arteries in his left leg; toe infection/ Osteomyelitis; toe pain right; toe redness; coldness in toe; This spontaneous case was reported by a physician and describes the occurrence of PERIPHERAL ARTERY THROMBOSIS (blocked arteries in his right leg  2 out of 3 blocked arteries in his left leg) and OSTEOMYELITIS (toe infection/ Osteomyelitis) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Emergency care (Received antibiotics as reported by the patient.), Ankle brachial index on 12-Feb-2021, Angiogram (completely blocked arteries in his right leg and 2 out of 3 blocked arteries in his left leg.) on 17-Feb-2021, Toe amputation on 28-May-2021 and Arterial bypass operation on 09-Apr-2021. Concurrent medical conditions included Metabolic syndrome. Concomitant products included HEPARIN and RIVAROXABAN (XARELTO) for an unknown indication.   On 03-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Feb-2021, the patient experienced PERIPHERAL ARTERY THROMBOSIS (blocked arteries in his right leg  2 out of 3 blocked arteries in his left leg) (seriousness criterion hospitalization). On an unknown date, the patient experienced OSTEOMYELITIS (toe infection/ Osteomyelitis) (seriousness criterion medically significant), PAIN IN EXTREMITY (toe pain right), ERYTHEMA (toe redness) and FEELING COLD (coldness in toe). The patient was hospitalized on 14-Feb-2021 due to PERIPHERAL ARTERY THROMBOSIS. At the time of the report, PERIPHERAL ARTERY THROMBOSIS (blocked arteries in his right leg  2 out of 3 blocked arteries in his left leg), OSTEOMYELITIS (toe infection/ Osteomyelitis), PAIN IN EXTREMITY (toe pain right), ERYTHEMA (toe redness) and FEELING COLD (coldness in toe) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient has a well controlled HBA1-C and no diabetes.   Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Chills; fatigue; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-healthcare professional).   A 58 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 22Mar2022 21:00 (Lot number: FM0698) at the age of 58 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1, single, Administration time: 14:00, Anatomical site of injection: Right shoulder, Route of administration: Intramuscular, Batch/Lot number: EP6955), administration date: 30Mar2021, when the patient was 58 years old, for COVID-19 Immunization, reaction(s): "Mild nausea and body ache", "Mild nausea and body ache", "Chills", "Malaise"; Bnt162b2 (Dose: 2, single, Administration time: 14:00, Anatomical site of injection: Right shoulder, Route of administration: Intramuscular, Batch/Lot number: EP6955), administration date: 20Apr2021, when the patient was 58 years old, for COVID-19 Immunization, reaction(s): "Mild nausea and body ache", "Mild nausea and body ache", "Malaise", "Chills".  The following information was reported: CHILLS (non-serious) with onset 22Mar2022, outcome "recovered" (Mar2022), described as "Chills"; FATIGUE (non-serious) with onset 22Mar2022, outcome "recovered" (Mar2022), described as "fatigue". Therapeutic measures were not taken as a result of chills, fatigue.   Additional information: Patient age at time of vaccination: 58 years. Anatomical site of injection for dose 3: Right shoulder. Dose 3 Batch/Lot number: unable to Locate or Read the Details and Expiration: not available. Complete only if a 3rd dose was administered. Booster dose due to high risk of frequent institutional or occupational exposure to coronavirus (and at risk of serious covid-19 complication). Weakened immune system, If the reason is a weakened immune system, please select one of the conditions below, Current or recent cancer (including blood cancers such as Hodgkin's disease, leukemias, and myelomas), Advanced or untreated HIV infection, Use Of medications that suppress the immune System (e.g., high dose of corticosteroids, cyclosporine, methotrexate, azathioprine, and biologic therapies like rituximab and etanercept), No non-functioning, spleen or kidney failure, Other was not reported. Prior vaccinations (Within 4 weeks) and Relevant tests were none. Specific relevant test for thromboembolic events with thrombocytopenia was none.   No follow-up attempts are possible. No further information is expected.
Daily headache that started 3 days after vaccination. Patient self treated with daily Tylenol 500mg Q8H for 2 weeks. No concerning neurological findings on exam. Discussed addressing stress patient reported and sleep disturbance patient reported.
Breastfeeding; This spontaneous case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding). At the time of the report, MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding) had resolved. Patient had the first 2 shots of COVID-19 vaccine of Moderna. She was supposed to have the 3rd shots of Moderna vaccine tomorrow. She had been breastfeeding her baby since day one. The child was almost 3 and she wanted to see if it would be safe to get that shot.  No concomitant and treatment medication were provided
Started with stuffy nose, completely clogged, then wheezing, by next morning was running a fever.  Complains of achiness and upset stomach.  Skin on face is red and blotchy.  Symptoms have not subsided at this time.
This spontaneous report as received from a healthcare worker refers to an unspecified patient of unknown demographics. No concurrent conditions or medical history was provided. On 05-AUG-2014 (reported as "today").the patient was vaccinated with an expired dose of PNEUMOVAX23 injection (lot # H013847; expiry date: 15-MAR-2014: dose, route of administration and indication unspecified). No concomitant medications were reported. No adverse effects were reported. Additional information is not expected as it was no consent to contact with reporter.
Febrile at 104 degrees; arthralgias; poor response to anti-inflammatories.
Tachycardia 4+ hours, 2 EKGs, diltiazem administered, atrial flutter determined after 2nd dose of diltiazem, cardioversion performed. Issue resolved after cardioversion.
Weird tingling or numbness of tongue and possibly lips 20 min post vaccine. No softness of breath, fast heart rate, etc. Black and blue spot noticed on underside of tongue later. Did not report to pharmacist. Drove home, took fexofenadine 180 mg, symptoms subsided, ate dinner, and went to sleep as usual.
fever; joint and muscle pain; joint and muscle pain; chills; headache; This is a spontaneous report from a contactable consumer (patient). A 66-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EN6200, Expiration date: unknown), dose 2 via an unspecified route of administration, administered in Arm Left on 02Mar2021 14:02 (at the age of 66-year-old) as dose 2, single for COVID-19 immunization. Medical history included spine issues and car accident from 2003 to an unknown date (she had spine issues from a car accident she had in 2003. She said she had been medicating with CBD oil and medical marijuana for the past 3 years. No further details provided), fibromyalgia from an unknown date and unknown if ongoing (she has had Fibromyalgia for 30 years), knee arthroplasty from an unknown date and unknown if ongoing (she had both knees replaced about 5 years ago). The patient's concomitant medications were not reported. The patient previously received first dose of BNT162B2 (Expiry Date: Unknown), via intramuscular, administered in Arm Left (at the age of 66-year-old) on 10Feb2021 for COVID-19 immunisation and experienced knees got so stiff/both her knees have stayed stiff. Facility where the vaccination was given unknown. Vaccine was not administered at Military facility. Number of previous doses was none. Patient did not receive any additional vaccines administered on same date of the Pfizer suspect. Patient prior vaccinations (within 4 weeks) were none reported. Patient reported that she had a reaction to her second Pfizer COVID-19 Vaccine. She clarified since 10:00AM this morning 03Mar2021 she has had a fever, joint pain, muscle pain, chills, and a severe headache. She clarified she got her second COVID-19 Vaccine shot yesterday 02Mar2021 at 2:00PM. She said her side effects started around 20 hours after she received her second COVID-19 Vaccine. Patient said she wanted to know what the usual time frame was for the COVID-19 side effects to go away. Reported she took 2 Rapid Release Acetaminophen 500mg capsules at 10:00AM this morning 03Mar2021: NDC Number: #, Lot Number: P120450, Expiration Date: Jun2022. Reported after she received her first COVID-19 Vaccine 10Feb2021, her knees got so stiff. She said she had both of her knees replaced about 5 years ago. She said both her knees have stayed stiff since she received her first COVID-19 Vaccine dose. Patient did not visit emergency room and physician office. There was no investigation assessment and no relevant tests. Therapeutic measures were taken as a result of fever, joint and muscle pain, chills, headache. The clinical outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Pt reports a raw, sensitive, painful area behind her left ear and neck area. No redness, blisters,or rash present.
Information has been received from a registered nurse referring to multiple unspecified patients of unknown age and gender. On unknown dates, the patients were vaccinated with improperly stored ROTATEQ (lot # M042170, expiration date of 22-JUN-2018 or M044396, expiration date of 19-JUN-2018 or M044397, expiration date of 20-JUN-2018 or N009948, expiration date of 21-OCT-2018; strength, dosage, frequency and route unspecified) for prophylaxis. No adverse effects were reported. Temperature was from 0 degree C to 1 degree C (0.8 degree C) for 52 minutes. The previous temperature was reported as from 9 to 25 degree C (10.9 degree C) for 3 hours 17 minutes. This is one of 5 cases received from the same reporter. Sender's Comments: US-009507513-1709USA007014: Original Case: 1709USA000054.
Urinary Tract Infection; This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (Urinary Tract Infection) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced URINARY TRACT INFECTION (Urinary Tract Infection). At the time of the report, URINARY TRACT INFECTION (Urinary Tract Infection) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Event outcome was updated to resolved.
This is a spontaneous report from a contactable consumer. A male patient of unspecified age received bnt162b2 (PFIZER-BIONTEC COVID-19 VACCINE, Solution for injection) both doses (Lot number: not reported) in Feb2021, both via unspecified route of administration as single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Patient was not diagnosed with COVID-19, prior to vaccination. Patient been tested for COVID-19, post and since the vaccination. On 10Aug 2021, patient was contracted COVID-19 and was fully vaccinated. Treatment received was unknown. Lab test included positive COVID-19 test on 10Aug2021. The outcome of event was not resolved.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Began with red welt size of half dollar, continues to grow.  Now the size of 8cm wide 12 cm tall.
PATIENT DESCRIBES SORES ON ROOF OF MOUTH THAT BEGAN LAST NIGHT 4 DAYS AFTER IMMUNIZATION
Patient received injection afternoon of 11/16/06. By 8:30pm eyes were swollen, shortness of breath, stiffness and pain neck and shoulders, nausea, dry mouth and eyes. Patient starting drink more water, used eye drops and inhaler. Eyes are still swollen and some lung irritation on 11/17/06.
Extreme shaking and chills,  large lump appeared on left leg thigh,  Pressure of top of head (left side) and painful throbbing on right side of neck.
pt recv vax 1APR96 & 14JUN96 pt devel a mild rash w/less than 20 lesions;subsequently devel chickenpox;pt tx DPH, APAP, calamine lotion & colloidal oatmeal (aveeno bath) & was doing fine;
Pain at injection site. Swollen on deltoid/shoulder with rash. May be ADR from vaccine vs cellulitis of overlying area per ID Dr.
Armpit pain shooting into body on left armpit and left side of body. Headache, fever, joint and muscle pain.
Lightheaded; Chills; Positive COVID test; No appetite; Low grade fever/fever of 100.6 F; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive COVID test), DECREASED APPETITE (No appetite), DIZZINESS (Lightheaded), PYREXIA (Low grade fever/fever of 100.6 F) and CHILLS (Chills) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for an unknown indication.     The patient's past medical history included Lung disorder NOS and Cough since an unknown date.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced DECREASED APPETITE (No appetite) and PYREXIA (Low grade fever/fever of 100.6 F). On 17-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Positive COVID test). On 20-Jan-2021, the patient experienced DIZZINESS (Lightheaded) and CHILLS (Chills). On 20-Jan-2021, CHILLS (Chills) had resolved. On 21-Jan-2021, PYREXIA (Low grade fever/fever of 100.6 F) had resolved. At the time of the report, SARS-COV-2 TEST POSITIVE (Positive COVID test), DECREASED APPETITE (No appetite) and DIZZINESS (Lightheaded) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Jan-2021, SARS-CoV-2 test positive: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information reported included Bamlanivimab infusion received on 20-JAN-2021. Concomitant medication was not provided.
The injection site became inflamed, and swelled to the size of a baseball. This condition lasted for 72 hours, and the inflamed portion was very tender during that period.